FINHUB Insights

DXCM · Q4 FY25 · Oct 1 – Dec 31, 2025

Dexcom Q4 FY25: where the revenue came from and where it went

Dexcom Q4 FY25: revenue $1.3B (+13% year over year). Net profit $0.27B. Largest cohort US $0.9B. The whole income statement as a sankey diagram from the SEC filing.

Period
Oct 1 – Dec 31, 2025
Reported
Feb 12, 2026 10-K
Sankey diagram of Dexcom's income statement for Q4 FY25: revenue of $1.26 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$1.26B +13% year over year
Gross profit$0.79B 63% margin
Operating profit$0.32B 26% margin
Net profit$0.27B 21% margin

The numbers

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
ItemValueShare of revenueYear over year
Revenue 1.26 100% +13%
US 0.89 71% +11%
Non US 0.37 29% +18%
Cost of revenue−0.4737%
Gross profit0.7963% margin+4pp
R&D−0.1512%−1pp
SG&A−0.3226%−4pp
Operating profit0.3226% margin+9pp
Tax−0.07
Net profit0.2721%+8pp
Filing on EDGAR More quarters of DXCM

Source of the numbers: structured XBRL data from the filing (10-K). The diagram is generated automatically and checked against EDGAR before release. The fourth quarter has no column of its own in an annual report, so it is the full year minus the first nine months. How we calculate it → About and methodology.